Featured Updates to the NCCN Guidelines

The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.

Charles A Enke | James L Mohler | Michael Kuettel | Eric Rohren | Andrew J Armstrong | A. D'Amico | P. Kantoff | J. Eastham | J. Pow-Sang | P. Walsh | E. Plimack | R. Bahnson | M. Roach | E. Horwitz | J. Mohler | A. Armstrong | C. Enke | T. Farrington | C. Higano | M. Kuettel | Sylvia S. Richey | Stan Rosenfeld | E. Small | S. Srinivas | J. Tward | Dorothy Shead | A. Cmelak | E. Rohren | Richard J Lee | A. Colevas | S. Strope | C. Stein | F. Worden | W. Lydiatt | E. Maghami | Philip W Kantoff | Patrick C Walsh | Mark H Kawachi | James A Eastham | Celestia S Higano | A. Malcolm | Eric J Small | Mack Roach | G. Macvicar | Robert R Bahnson | Michael Cohen | Anthony Victor D'Amico | Thomas A Farrington | Eric Mark Horwitz | Gary R Macvicar | Arnold W Malcolm | David Miller | Elizabeth R Plimack | Julio M Pow-Sang | Sylvia Richey | Stan Rosenfeld | Sandy Srinivas | Cy Stein | Seth A Strope | Jonathan Tward | Dorothy A Shead | Maria Ho | M. Kawachi | M. Ho | David Miller | D. Pfister | Michael Cohen | Nicole R Mcmillian | J. A. Ridge | Maura L. Gillison | Jatin P. Shah | Gregory T. Wolf | Robert I. Haddad | David M. Brizel | Frank Dunphy | Jill Gilbert | Bruce H. Haughey | Wesley L. Hicks | Ying J. Hitchcock | Renato Martins | Bharat B. Mittal | Sandeep Samant | David E. Schuller | Sharon Spencer | Randall S. Weber | K. Ang | B. Burtness | Paul M. Busse | Jimmy J. Caudell | David W. Eisele | Merrill S. Kies | Thomas V. McCaffrey | Harlan A. Pinto | S. Yom | Miranda Hughes | Maura L Gillison | Jimmy J Caudell

[1]  J. Wolff,et al.  Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial , 2012, BJU international.

[2]  T. Tammela,et al.  Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects. , 2013, European urology.

[3]  G. Roodman Mechanisms of bone metastasis. , 2004, Discovery medicine.

[4]  T. Tammela,et al.  The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. , 2012, The Journal of urology.

[5]  U. Steiner,et al.  Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer , 2007 .

[6]  C. Divgi,et al.  Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  L. Klotz,et al.  Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care? , 2012, Current oncology.

[8]  I. Tannock,et al.  Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Henriksen,et al.  Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. , 2002, Cancer research.

[10]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[11]  J. Cuzick,et al.  International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta‐analysis of 1446 patients , 2007, BJU international.

[12]  S. Daneshmand,et al.  Androgen deprivation therapy: evidence‐based management of side effects , 2013, BJU international.

[13]  A. Bono,et al.  Intermittent Androgen Deprivation for Locally Advanced Prostate Cancer , 2003, Oncology.

[14]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[15]  J. Roeske,et al.  Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[17]  S. Pocock,et al.  Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. , 2006, JAMA.

[18]  V. Ratanatharathorn,et al.  Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. , 2009, Journal of palliative medicine.

[19]  Joseph L. Chin,et al.  Intermittent Androgen Suppression for Rising PSA Level After Radiotherapy , 2013 .

[20]  S. Goldenberg,et al.  Effects of intermittent androgen suppression on androgen‐dependent tumors. Apoptosis and serum prostate‐specific antigen , 1993, Cancer.

[21]  J. Crook,et al.  Androgen deprivation therapy: minimizing exposure and mitigating side effects. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[22]  Thomas J. Smith,et al.  Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Donna L Berry,et al.  Intermittent versus continuous androgen deprivation in prostate cancer. , 2013, The New England journal of medicine.

[24]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[25]  P. Bonnet,et al.  Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. , 2002, Clinical prostate cancer.